Latest Market Indices News

Spartan Resources Limited will be removed from the S&P/ASX 200 index following its acquisition by Ramelius Resources, with Infratil Limited stepping in as its replacement.

Botanix Pharmaceuticals reports robust early sales and expanding prescriber engagement for Sofdra™, its FDA-approved topical gel for excessive underarm sweating, signaling promising growth ahead.

S&P Dow Jones Indices has announced its June 2025 quarterly rebalance, with notable additions and removals across major S&P/ASX indices effective June 23. These changes reflect evolving market dynamics and could influence investor portfolios.

Regal Partners Limited reported a stellar 2024 with a 141% jump in average funds under management to $14.4 billion and a near tripling of net profit after tax. Strategic acquisitions and offshore expansion underpin its growth trajectory.

WAM Active has delivered a remarkable 32.5% investment portfolio growth in 2024, significantly outperforming key market indices and declaring a fully franked interim dividend of 3.0 cents per share.

Matsa Resources has advised shareholders to take no immediate action following Patronus Resources’ unsolicited takeover offer, with a formal recommendation expected soon.

Nutritional Growth Solutions reported a slight revenue decline in Q4 FY24 but remains optimistic about growth and profitability in FY25, buoyed by renewed Walmart partnerships and expanding Asian distribution.

Mayfield Group Holdings has declared a $5 million special dividend alongside its interim payout, signaling robust financial health and confidence in sustained growth.

Imperial Pacific Limited reports a $652,000 net gain for the half year ending December 31, 2024, driven by strong investment performance and an increased dividend, despite ongoing challenges with its Excelsior Capital stake.

London City Equities Limited reports a robust 12% increase in its investment portfolio for the half year ending December 2024, driven by strong Fiducian Group performance and strategic share sales, enabling higher dividend payouts despite ongoing legal challenges.

Chrysos Corporation reports a robust Q2 FY25 with a 12% quarter-on-quarter and 53% year-on-year revenue increase, driven by expanding international sales and rising sample volumes. The company secured two new contracts, boosting its PhotonAssay™ footprint and maintaining strong financial health.